Balyasny Asset Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Balyasny Asset Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,740	Closed	-$185K	–	3249
2024 Q1	$185K	Buy	+11,740	New	+$181K	﹤0.01%	2427
2023 Q1	–	Sell	-1,393	Closed	-$22.8K	–	3274
2022 Q4	$22.8K	Sell	1,393 -56,983	-98%	-$927K	﹤0.01%	2467
2022 Q3	$1.08M	Buy	+58,376	New	+$916K	﹤0.01%	1764
2018 Q2	–	Sell	-10,000	Closed	-$200K	–	2233
2018 Q1	$200K	Buy	+10,000	New	+$253K	﹤0.01%	1768

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Balyasny Asset Management's DCPH Position: Q2 2024 in Review

Balyasny Asset Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 11,740 shares — an estimated $185K sold.

Balyasny Asset Management first reported a position in DCPH in Q1 2018 and held it in 4 quarters. The position peaked at $1.08M in Q3 2022. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

Balyasny Asset Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Balyasny Asset Management sold 11,740 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $185K.
Balyasny Asset Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 4 quarters.
Balyasny Asset Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $1.08M in Q3 2022.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.